Statement re US Patent Allowed

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

                            Allowance of US Patent                             

                     on Isobaric Tandem Mass Tags® (TMT®)                      

                      Allowance of European Patent (TMT2)                      

30 July 2007. Proteome Sciences plc ("Proteome Sciences") is pleased to
announce that the USPTO has issued a Notice of Allowance for its US patent
application in isobaric mass labelling for its tandem mass tags (TMT®) entitled
"Mass Labels" Serial No. 10/221,666 (TMT1). The Notice of Allowance completes
the final stage of patent examination and represents the form in which the
patent will be granted. This follows grants of the corresponding cases in
Australia, New Zealand, Canada and most recently in Europe. The US Patent
contains broad claims to sets of isobaric mass tags.

The TMT1 Notice of Allowance in the US is a significant milestone for Proteome
Sciences because it confers valuable intellectual property around isobaric mass
tagging in another major market and enables the Company to approach entities
using isobaric mass labels in the US and to alert them that they can obtain
licences from Proteome Sciences for the manufacture or use of any type of
isobaric mass tags in their research programmes. These licences will allow
revenue to be generated from any applications in the field of isobaric mass
tagging.

Proteome Sciences has also received a Rule 51(4) - Notice of Intention to Grant
for its patent application entitled "Mass Labels", Serial No. 02767650.1 (TMT2)
from the European Patent Office that was published on 21st May, 2007. The TMT2
European Patent claims isobaric mass tags with peptide structures and various
methods of their use.

Commenting on the US Notice of Allowance, Christopher Pearce, CEO of Proteome
Sciences said:

"The allowances of the TMT1 patents in the US and Europe have provided Proteome
Sciences broad claims across the field of isobaric tandem mass tagging with the
ability to now exploit TMT® in these substantial markets, both as a product, in
its own right and for third party licences for the manufacture or use of any
type of isobaric tandem mass tags.

The market and applications for isobaric mass tagging in quantitative mass
spectrometry continues to grow at a rapid pace and we are delighted to have
achieved such broad patent coverage in the major economies. The latest patent
grants should now enable us to complete commercialisation of TMT® through
outlicensing and to generate strong revenue through licence income, product
sales and royalties."

                                     Ends                                      

Notes to editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications. It has discovered blood biomarkers
principally for stroke, vCJD, BSE, brain damage, solid organ transplant
rejection and Alzheimer's disease. The main focus of its research currently
addresses neurological, neurodegenerative, oncology and cardiovascular
conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification and validation of potential biomarkers and drug targets,
including specialisation in membrane proteins and protein phosphorylation.

The Company has developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer®, PST®, qPST™ and TMT®. Proteome Sciences has patent
allowances in the major global jurisdictions for isobaric tandem mass tags (TMT
®) for the manufacture and use of any type of isobaric mass tags.

Commercialisation is actively pursued across the portfolio of the Company's
programmes and technologies with licensing deals signed in biomarkers for
Stroke and TSEs and for ProteoSHOP®.

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and Frankfurt Innovations
Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its
corporate and business development staff, and has collaborative research
agreements with leading academic institutes. The Company is listed on the
Alternative Investment Market.

For further information please visit www.proteomics.com .

Proteome Sciences plc

Dr. Ian Pike, Business Development Director

Email: [e-mail]

Christopher Pearce, Chief Executive Officer

Email: [e-mail]

Tel: [phone]

                               Public Relations                                

IKON Associates Coast Communications

Adrian Shaw Matt Baldwin

Tel: [phone] Tel: [phone]

Mobile: [phone] Mobile: [phone]

Email: [e-mail] Email: [e-mail]

Nominated Adviser

Teather & Greenwood

Gareth Price / Thilo Hoffman Tel: [phone]